NCT03313271

Brief Summary

Lymphoma is the most common hematologic tumor. It is derived from lymphoid tissue, including Hodgkin's lymphoma(HL) and non Hodgkin's lymphoma(NHL). The treatment of lymphoma includes chemotherapy, radiotherapy, stem cell transplantation, targeted therapy and surgery etc. With the progress of treatment, the survival rate of lymphoma patients has been improved. But the 5 year survival rate of lymphoma in China is shorter than that in United States. The reason is that there is still a gap between China and the United States in disease screening, diagnosis and treatment. Observational studies, especially cohort studies, are important tools for understanding disease progression, treatment, and prognosis in the real world. Observational cohort studies which involve over 500 patients are currently launched by South Korea and the United States. China, which has more patients, doesn't have a cohort of patients with lymphoma. So the primary objective of this study was to establish an observational cohort of patients with lymphoma in China and follow up the patients for a long period of time to provide basic support for clinical research and drug development, and continuously improve patient outcomes and quality of life. The secondary objective is to collect information about diagnosis, treatment, follow-up and prognosis of lymphoma.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
5,000

participants targeted

Target at P75+ for all trials

Timeline
16mo left

Started May 2017

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress87%
May 2017Aug 2027

Study Start

First participant enrolled

May 17, 2017

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

October 11, 2017

Completed
7 days until next milestone

First Posted

Study publicly available on registry

October 18, 2017

Completed
9.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 17, 2027

Expected
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 30, 2027

Last Updated

October 18, 2017

Status Verified

October 1, 2017

Enrollment Period

10 years

First QC Date

October 11, 2017

Last Update Submit

October 17, 2017

Conditions

Lymphoma

Keywords

lymphomaCLAPChinapatient registry

Outcome Measures

Primary Outcomes (1)

  • Characteristics of lymphoma in China，

    Understand the characteristics of lymphoma in China,such as the distribution of sex,age,histological type and clinical stage etc

    5 years

Secondary Outcomes (1)

  • Overall survival

    10 years

Study Arms (1)

a cohort of patients with lymphoma in China

establish a cohort of patients with lymphoma in China and follow up the patients for a long period of time

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Lymphoma patients in 5 hospitals

You may qualify if:

  • The disease was diagnosed by Hodgkin's or non Hodgkin's lymphoma
  • years of age or older at diagnosis
  • The diagnosis was confirmed within 6 months before admission
  • Informed consent was obtained

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Peking University Cancer Hospital

Beijing, Beijing Municipality, 100142, China

RECRUITING

Related Publications (4)

  • Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32. doi: 10.3322/caac.21338. Epub 2016 Jan 25.

    PMID: 26808342BACKGROUND

  • Zeng H, Zheng R, Guo Y, Zhang S, Zou X, Wang N, Zhang L, Tang J, Chen J, Wei K, Huang S, Wang J, Yu L, Zhao D, Song G, Chen J, Shen Y, Yang X, Gu X, Jin F, Li Q, Li Y, Ge H, Zhu F, Dong J, Guo G, Wu M, Du L, Sun X, He Y, Coleman MP, Baade P, Chen W, Yu XQ. Cancer survival in China, 2003-2005: a population-based study. Int J Cancer. 2015 Apr 15;136(8):1921-30. doi: 10.1002/ijc.29227. Epub 2014 Oct 3.

    PMID: 25242378BACKGROUND

  • De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, Trama A, Visser O, Brenner H, Ardanaz E, Bielska-Lasota M, Engholm G, Nennecke A, Siesling S, Berrino F, Capocaccia R; EUROCARE-5 Working Group. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study. Lancet Oncol. 2014 Jan;15(1):23-34. doi: 10.1016/S1470-2045(13)70546-1. Epub 2013 Dec 5.

    PMID: 24314615BACKGROUND

  • Australian Institute of Health and Welfare. Cancer survival and prevalence in Australia: period estimates from 1982 to 2010. Asia Pac J Clin Oncol. 2013 Mar;9(1):29-39. doi: 10.1111/ajco.12062.

    PMID: 23418847BACKGROUND

MeSH Terms

Conditions

Lymphoma

Condition Hierarchy (Ancestors)

Neoplasms by Histologic TypeNeoplasmsLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesImmunoproliferative DisordersImmune System Diseases

Study Officials

  • Jun Zhu, Ph D

    Peking University Cancer Hospital & Institute

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Yuqin Song, Ph D

CONTACT

0086 ‭13683398726‬songyuqin622@163.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
OTHER
Target Duration
5 Years
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Director of lymphoma department

Study Record Dates

First Submitted

October 11, 2017

First Posted

October 18, 2017

Study Start

May 17, 2017

Primary Completion (Estimated)

May 17, 2027

Study Completion (Estimated)

August 30, 2027

Last Updated

October 18, 2017

Record last verified: 2017-10

Locations

CN(1)